Skip to main content
main-content
Top

12-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: Phase IIb study of fenebrutinib in RA patients

share
SHARE
print
PRINT
insite
SEARCH

Lead investigator Stanley Cohen discusses the key results for the multi-dose trial of fenebrutinib versus placebo and adalimumab in patients with rheumatoid arthritis refractory to methotrexate or prior tumor necrosis factor inhibitor therapy (2:05).

share
SHARE
print
PRINT

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.